|
Androgensa
|
Infant sex
|
Outcomes
|
|---|
| | |
12-month AOSI
|
36-month SRS
|
|---|
| | |
Beta
|
95% CI
|
P
|
Beta
|
95% CI
|
P
|
|---|
|
ln(T)
|
Female (n = 62)
|
0.20
|
(−0.12,0.51)
|
0.22
|
−0.06
|
(−0.30,0.19)
|
0.64
|
|
Male (n = 75)
|
0.20
|
(−0.13,0.52)
|
0.23
|
0.05
|
(−0.25,0.36)
|
0.73
|
|
ln(A4)
|
Female (n = 62)
|
0.06
|
(−0.36,0.48)
|
0.78
|
−0.18
|
(−0.50,0.14)
|
0.26
|
|
Male (n = 75)
|
0.06
|
(−0.33,0.45)
|
0.76
|
−0.21
|
(−0.57,0.15)
|
0.24
|
|
ln(DHEA)
|
Female (n = 62)
|
0.09
|
(−0.19,0.37)
|
0.51
|
−0.05
|
(−0.25,0.16)
|
0.67
|
|
Male (n = 75)
|
0.04
|
(−0.28,0.34)
|
0.82
|
−0.01
|
(−0.31,0.29)
|
0.94
|
-
ln natural log transformed
-
aSeparate robust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge (SRS raw) scores. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale (SRS) total raw score
